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1)ep.lrtnll'J1[ of ledlC.•] Ill'rohwlog, Ro al Free and UnlV"l,lty Colleg,- Medl~al S hool. London, K
CIIII .1/"1<,/,,,,1 b!lt'(/ 21)1)(1: (, (. Uppll'lIll'llt .'): 7(J-H I
M,lny annhllllll', ,He u~,'d "lIlpln~,llly, I.,'. wuhout knowkdge
of "jth,'r lilt' 1l,lmrc "f th,' p,\tho~en or it, cn51llvlty l(l
anllhlOnC\ (It 1\ Inrcrc,nn~ ttl not,' In P:lSSlIlg th,lt till' word
empmral ha~ two me,lnlllg" III the Ellghsh 1:1I1~"lIa~e: (I) 'ba cd
llll or gllldnl hv lh,' r"'lIlts (If "hSerVall(lIl,'r ,'xp,'nlllcnt 01'11,,':
(II) 'pcrUlIllllg to lhe pranlce of pllY'It' or surgel. WldlOUI
~nellli/it' knowledg,,·I). Sill'll lISe I' nlien t,'nn"d 'hl'>l ~uess', In
t'ertam C.1St'S. e.g. Inl~'cril1m of the ruinary , r respiratory traers.
Ihe type o( inl~cnllg orgamslll IS brgely predinahk, althollgh
nowadays C115111\'lty pattenl$ Illay well not he, In olher ~as...s,
e,g. s,'prica<.'ll11a, th..: IIlI~cn\'t' cnolol-.'Y cannot he fon:casl with
JCCIi acy. amI IhllS J hro.ld-spe trum .1II0!llOtIC has to he IIs..:d.
Jllt~cn,)m .1 qlllred and tre, I'cd In Ihe cOl'l1n unity arc rardy
subject to laborawry-h"sed nucrohiolo¢cal cOllfinllanon. alld
\0 elllpiricaJ us,' 0 ,lIltihi tic~ under th"lc drCUlllSl.ln t"\ I~ tilt'
nsua] I'r,lt'tlce
In ordt'r to .:I100\e ;\11 annhioric for empirical u e by lIlean,
of ,\ ratIOnal q;\enlljjc 1'1'0 ess, the tirst ron. idt'ratiom aI','
spectrum of activity. rhanllacokjll~'rl(s and phannaco-
dVllanllcs. alld pan"1ll acCt'ptalllhty, It I~ llllPOrt:lI1t to consal..:r
t'ach pam·11t w 11<" Ireated on an IIldlVldll, I basI, ApplrC:ltiOIl of
these f.1t'tors to the particular c.1~e III {Iue tl 11'1 will olt,'n
narrow down the choic,' f ,ullihiotk to a few priom. at
whIch POint the provell rra k record {f c, ch in th' spe'itir
Il1dlCanOn IlUlst be taken IIltO account. ften the physICIan IS
In the fortunat" posmon ofbeinf: able to make a selt- tlon /i'01ll
a numher f SlllLlble c Illpounds. bllt more aIIII l'IIore
(ol1llnonly, due nl.1l1lly 10 the ol\-~oillg macaw in b, ten,11
reSl\tall c, the dlOI l' I l",cOlllln\;: severdy restrine I.
USE OF CEFIXIME IN COMMUNITY·ACQUIRED INFECTIONS
Ag:llnst till hat'kgroulld. It 1 instructive ttl cOltlider the role ai'
the third-generation oral cephak Ip nn, 'e/iXlI1w, 111 the
tn:.mllcnt of cOllullul1lry-acqulfl:d Il1fe-nons.
ResplralOry II1fcetl ns :md IItlecnolls of the IInnary rra 't an'
amollg rhe I1IOlt Olll11l0n reasons tor a pattcm I cek help
fj' III his/her tanuly do t Jr,
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BACTERIAL A£TIOlOGY
Rril'irn/or)' ,,!fi'crioJls The ba(lenal srt"Clt' most Olll11l0nJy
Illlphcat..:cl III COlllllllllllty-.1Ctjllircd rt'>plf:lrory tract mfecllnm
,Irc SII1·1'1"/I'm!.. I!HI',"''''U''''', ~hel\1olytiL trepto 0 'Cl (II ually
of Lall~dil'ld gmup A), I-IlIl'mpJ'lJilw IIIf'Il,''':dr and "'''''1.\'rlla
rtllalThalis. Thll~, such specl"~ nl:Y be respol1SlhI.: (or
pharyngitIS. ouns media, SIllUSIU~, acute bronchlUt ,1I1d ~nJ[e
t'xacerUatlOl1S of ChrolUl' broJl hm. 'et'iXJIlIt' IS )H~h]y acU\·...
agalllll all srr~lm of group A StTeplOCOc I, 1-1. U!fiIlWZd" and ,\I
(,It.1rrlhllil whetht'r or n I t1wy product' p-l.lcrama t', ,md allo
a~aill" pcnicillin-'l'nsiti\'t· 'trajns o( rneum COCCl. PnllClllll1-
TC'I~tallt plle\Il\IUCOCCI ,1fe re,islalll 10 alixJJllc, but such ,trams
arc still 111 a nllnonty III most gcognpluC-ll rca. Thus the
'pecmlltl of aCDvlty of ce/ixllllt' IS SUIL1blc lor m(cctJom of tim
body sy\tcm.
Lln'/I"')' il!(mi,'u MOH IInnary mfct'tlOn J qUlr..:d outsld..:
hmpiraJ are' du,' 10 t'ithcr F.srln'rirlritl (oli (~ S'}i,) or
"tlJ'Ir),I"(,>rrus ""prvl'iJl'linu' (1 fWo-I5%). The rell1;Jinder aTe
caused by a variety of enterobacteria. E. (illi I, hl~Lly
sensitive 10 Ct'fiXll11":, ~nd ,mpicill1n-reslSlafit str:uns remam
sl'mltivc dill' to thl' f: CI that efixime tS stable 111 the pre cncc
fTIM p-I:rcramase. ,. 5"I""I,III'li 11$ it nl I "cry slllcl1'uhlc to
'eftxil1lt:" (M I ,,;; 64 ~lg/mL) [1], but, be.-anng in mimi the
ch.lr.1ctcrimc~ of IInllary ex 'retlon o( dlt' drug, Cdi"OJ11C appears
suitablt· for rrcaring urin:lry infections due to 111.1 sp,'cic.
PHARMACOKINniCS AND PHARMACODYNAMICS
CdiXl 1\1t'. alth IIgh n t compl'l'cly ab rbed by 11'1 lith,
m-verrhc!t-ss rca hes lIlicrl1biol gically ad,'quJtc conccntrations
III ,nom hody ti5.$UI'S. FollowlIIg J los,' of -lOI) I\1g. J ""X f
-1.4 ~lglrllL I ,Ichlewd alier 3,5 h 121. The: half-life of cdiXlnll:
\> abollt 3.5 h. re ultmg 111 a rhmmcokmctlc profile (Figure I)
from wlllch IT call It' scen that the paf:lmt'tcr I > M IC I~ in
excess 0 711% of the dosmg 111 ceTVal (2-1 h) or thc
!'ncullI co lIS, M, ((1111"/1 "ii, gr Ill' A treptoco I and 1-1.
i"f/I/l·"zal'. Ii regarded as being imporunr for 'vel)'
dfl' tiV<' tre, t11lenl' 13],
Approximatel • 2()"1o of the adl1linJ~tcred dose of cdiXlnJe
appears in thc urinc (an equJ] amount IS e cretcd III the bIle).
TIllS giws concentrations of a rive antiblotlc suffiCIent to
inhihit thc l1l:lJor pJthogcn 'au5111g llnllary Il1fecrions.
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Figure 1 Relotlonsh,ps between blood
levels followmg a 400·mg dose of cetixime





COMPUANCE AND ADVERSE EVENTS
It is clearly [undamenralllllJl reao e that any drug be taken
pre cnbed. alth ugh it eCtllS likdy that. a~ • nribiotlcs arc
usually given in to high a dose [or to long. mall c.Jcvi. tiOI
should not cause igniJicam problem. olllpliance i a p ody
understood subject. but it i.'i clear that a once..daJly regimen i
more likely to be followed by the patient than if 3 medicine
h:u to be taken more otten dUll dllS [41. efLxil'lle, due co i
Ion' half-life, i.~ given once daily, dearly an advant. ge Over
m ny other SImilar compound~.
efixtlne often u ed (; r paediatric patien~, ami much of
success is due to the f.ICt that the su pension h. s a very
pleasam t:lStc. Tim is dearly conducive to good compliance.
Adverse events folJowmg cefixlIl) are III mJy g;u;ttomtes-
nnal disturbances. and a wide range of incidence has been
rep rted. Variati ru. appc.lr to be onnectl:d with tbe
natlOnaliry of the patient groups '[Sf,-'wlrech 1" , due. to
observer bi:u or is a genuine phenomenol! rc:quires fumler
investlg;ltion. In general. cefuame L~ regarded a.~ no more and
no les bable to cause: adverse even than similar drugs.
The cOl1lblIlation of e e 0 d=lsrratloll. once-daily
reglJllen and lugh toler3blury Icarly nuke for good
c mpliance.
CLINICAL EffICACY
A large noncomparative study (427 evalU<lble patienu) camed
Ollt 10 the commumty bowed that cefuume \ etfe tlve in
lower r piratory rra infections and ooris media in adults and
hudren [6). omparative srudic:. demonstrated that cefucime
was. c:ffective s d. nduomyclIl r c03Jl10xi lav in . dults an
children. respectively, with COnulllllury-acquircd lower r -
piratoty illfections [61. A 5-day course of 4 0 mg once daily
w hown to be as effective as ttCOlt:nlent for 10 days (71. Good
re uJts found in upper respi. tory infectiol!.! have been
ulll.lll3rized [21. aJld specifi tn I described [8,9). Of
particular note IS the report by W~ [Ill) of a trial involving
over 25000 chLldrcn with oOtLS Uledi .
For me treamtcOl of uncompH red urinary il fewons,
cefixime IU$ been h wn to b as effective as am Xl illin or
commoxazole [2), f especial intere t' the report by A. bach
[1 II, indJc ting th.t a ingle dose f cl'li Jme UOO mg) W3.l
effective in young adult women. A larger stlldy to confinn th~
result i needed.
USE OF CEFIXIME IN SWITCH THERAPY
wit h therapy. the practice of a rapid hange {rom parent'raJ
raJ ttc tmlllt. can u ually be Impkmenrcd after 2 or 3 days.
Switch therapy has conSiderable advanragc.~ to the patient. and
offers the chance to 01.<1ke cost saVlngs. There is grc t potential
for cefiximc to be used :u dIe oral ann in uch a strategy. TIlls
t pi has bcen reviewed recendy [121.
PROSPECTS
,e6xime h. s be~n available for general usc for about I() y~r ,
and ha.~ now become stand:trd therapy in orne counrri for
treaong respiratory and urinary tnt t jofl' ti m. Its u age ould
clearly be expanded to covet gonorrh ea [II], and itS
phatll1:lcokinetic behavior ugge<its m t biliary infection.~ could
be an ther indication. Pcrhap the great(."$t jncrea.~c in efixime
usc can be predi ted to be in . vitth therapy. Thi\ 111 n. ge-
mcnt strategy will undoubtedly become more widdy pra used
only for fin:mcial re:lSOO5. . tid cefixime Ius already
e rabluhed Itself as a leading contender.
It IS becoming re hzed thar intravenous therapy is being
overu~ed; not all patients wh presently receive illtt:1vctloU
dlerapy ,.,/, ;,,;Iio in fact rcqulTI: it [13J. A good ex. mple L\
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I'''dolll"!'hno\, ",h,'r" l ,lllrt'.lun"lIl 1I1Jy 'llit'll Ilt' s.lO l:lCfOry
1141. I'rnndt'd .he pJ!lt'1l! 1\ not nllllltlll~. Thl\ ~ ellJnO It
;lIlOtha "xJ1I1pll" of wherl" cdixlIlll" Ute could Ill" Incrcased.
whcd"'r III a h'hl\lul '''lUllg or 111 the COllllnllllllY
FIIl,lIJ),. lhl' I ck o( Jcm'lry of cdixlJllc ,lg.lJlISt S. ,lIIf,·II. Illay
Il,' a p tltl\'" Jd\',lIlugc. IrlJcClahk t1nrtl-gcllc ,[J,lIl l"ph 10'-
I'nnll\ (th.lt ,u,' ,I 'Uvc .1l;.lImt S 111/0'/11) .If,' fecngl1lznl :\.t
\lglllfic.lIll mk ,: ,tn 1151 ( r th,' ,'I1ICfg,'1\l c: of ll1l"dllnIl1l1-
rnlst;lJll S, tllln'lI, ( 1I~.sA). Ull ,/ rm,'n !.'TolJlld II 011 b,'
afglled thaI oll1poulld such ;1\ chxlI1ll". lI1a tlVl" a!-'lI1I1s1 S.
'11In'IIS, \ ould unt sdc:ct tor RSA. aud thus ItS usc ma hl"
prd'a,lhk unda C,'flalll nr 1l1l1stanccs tel J(S IIIJt'l'tJblc .1uaJ0W',
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